Feb 19, 2020
James Brown DVM, CEO, DURECT Corporation talks about how DURECT is advancing epigenetic therapies to treat alcoholic hepatitis and non-alcoholic steatohepatitis (NASH). The company's lead asset, DUR-928 has demonstrated promising therapeutic potential treating patients with alcoholic hepatitis, a life-threatening acute liver disease caused by chronic alcohol abuse with no approved drugs for treatment. Dr. Brown also talks about his background as a doctor of veterinary medicine and his goal to continue developing medicines that improve the lives of others.
#AlcoholicHepatits #Epigenetic #NASH #LiverDisease